- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Brain MRI-Based Software for Assessing Cortical Disarray Measurement
The CDM Insights software, which can be utilized with scans from 1.5T and 3T MRI, reportedly provides new measurements of cortical thickness and brain microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for CDM Insights, a magnetic resonance imaging (MRI)-based software that may facilitate early detection of neurodegeneration.
The cloud-native CDM (Cortical Disarray Measurement) Insights software enables neuroradiologists to assess new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brian Diagnostics, the developer of the CDM Insights software.
For the assessment of brain MRI, the newly FDA-cleared CDM Insights software provides neuroradiologists with new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brain Diagnostics, the developer of CDM Insights. (Image courtesy of Adobe Stock.)
"Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage,” noted Steven Chance, Ph.D., the CEO and co-founder of Oxford Brian Diagnostics. “These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease. Ultimately, this enables providers … to understand patient brain structure changes prior to symptom progression and improve patient outcomes."
The company said CDM Insights allows clinicians to monitor brain changes across multiple stages of adult life and enables assessment of patients with neurodegenerative disorders such as Alzheimer’s disease. The software can be utilized with scans from 1.5T or 3T MRI devices, according to Oxford Brain Diagnostics.
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
